Results 131 to 140 of about 16,072,038 (292)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Best-fit parameters resulting from modeling of HDL-C levels as a function of apoA-I and apoA-II levels and comparison of resultant predicted values of mean HDL-C levels with observed values of mean HDL-C levels in the female low HDL-C/high CRP subgroup (HR1) and the female high HDL-C/high CRP subgroup (HR2).

, 2013
Best-fit parameters resulting from modeling of HDL-C levels as a function of apoA-I and apoA-II levels and comparison of resultant predicted values of mean HDL-C levels with observed values of mean HDL-C levels in the female low HDL-C/high CRP subgroup ...
Stephan J. L. Bakker (111215), Robin P. F. Dullaart (196402), James P. Corsetti (319049), Charles E. Sparks (319053)   +3 more
core   +1 more source

Association between markers of cardiovascular risk and clinical parameters of periodontitis

Revista de Odontologia da UNESP
INTRODUCTION: Periodontal disease is an inflammatory response to bacteria that reside in the gum tissue and can have systemic repercussion. OBJECTIVE: The aim of this study was to assess the relationship between periodontitis and markers of ...
José Eduardo Gomes Domingues, Mario Vianna Vettore, Emerson Silva Lima   +2 more
doaj  

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study

Chang Jiang,1,2 Maichao Li,1,2 Ying Chen,3 Yuwei He,1,2 Xinde Li,1,2 Lingling Cui,1,2 Han Qi,1,2 Zan Cheng,1,2 Xiaoqing Zhang,3 Changgui Li,1– 3 Jie Lu1– 3 1Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Qingdao, People’s ...
Li X, He Y, Li C, Cui L, Qi H, Zhang X, Lu J, Jiang C, Chen Y, Li M, Cheng Z   +10 more
core  

Evaluation of triglyceride: HDL-C ratio and Non-HDL-C as harbingers of increased cardiovascular risk in metabolic syndrome

, 2016
Background: Metabolic syndrome is an aggregate of conditions that together increases the risk of developing cardiovascular disease and type 2 diabetes mellitus.
R., Dharuni, R., Harish, H. L., Vishwanath, B. V., Maruthi Prasad   +3 more
core   +1 more source

Elevated non-HDL-C to HDL-C ratio as a marker for NAFLD and liver fibrosis risk: a cross-sectional analysis

Frontiers in Endocrinology
BackgroundDyslipidemia is a known independent risk factor for Nonalcoholic fatty liver disease (NAFLD). However, the relationship between NAFLD and the serum non-high-density lipoprotein cholesterol (non-HDL-C) to high-density lipoprotein cholesterol (HDL-C) ratio remains unclear. This study examined the association between the non-HDL-C to HDL-C ratio
Yanyan Xuan, Yanyan Xuan, Yanyan Xuan, Minghui Zhu, Linzhi Xu, Shujiao Huangfu, Tongyu Li, Chunbo Liu, Dongdong Zhou   +8 more
openaire   +3 more sources

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

HDL-C Levels (mg/dl) by history of weight cycling and obesity status^*.

, 2018
HDL-C Levels (mg/dl) by history of weight cycling and obesity status*.
Marian B. Olson (6038039), Nathaniel Reichek (3741628), C. Noel Bairey Merz (460043), Steven E. Reis (113658), Sheryl F. Kelsey (560351), Eileen Handberg (491632), Vera Bittner (4036847)   +6 more
core   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source